American Vanguard Corp: Form 10-Q for the period ended Mar 31, 2017
Filed with the SEC on May 4, 2017 and accepted by EDGAR at May 4, 2017, 16:01 ET.
Management's discussion and analysis
As filed, 28,284 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
FORWARD-LOOKING STATEMENTS/RISK FACTORS:
The Company, from time-to-time, may discuss forward-looking statements including assumptions concerning the Company’s operations, future results and prospects. These forward-looking statements are based on current expectations and are subject to a number of risks, uncertainties and other factors. In connection with the Private Securities Litigation Reform Act of 1995, the Company provides the following cautionary statements identifying important factors which, among other things, could cause the actual results and events to differ materially from those set forth in or implied by the forward-looking statements and related assumptions contained in the entire Report. Such factors include, but are not limited to: product demand and market acceptance risks; the effect of economic conditions; weather conditions; changes in regulatory policy; the impact of competitive products and pricing; changes in foreign exchange rates; product development and commercialization difficulties; capacity and supply constraints or difficulties; availability of capital resources; general business regulations, including taxes and other risks as detailed from time-to-time in the Company’s reports and filings filed with the U.S. Securities and Exchange Commission (the “SEC”). It is not possible to foresee or identify all such factors. For more detailed information, refer to Item 1A., Risk factors and Item 7A., Quantitative and Qualitative Disclosures about Market Risk, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.
MANAGEMENT OVERVIEW
Overall financial performance for the Company improved for the quarter ended March 31, 2017. Our net sales for the period increased 2% to $70,673, as compared to $69,474 for the first quarter of 2016. Our gross profit performance ended at $30,084 or 43% of sales, as compared to $27,053 or 40% of sales for the comparable quarter last year. Operating costs in the quarter increased from 33% of sales in 2016 to 35% of sales this year, including increased marketing spend, as the 2017 growing season progresses, higher accruals for long-term incentive compensation and further investment in developing our SIMPAS delivery system. At the same time our net income increased by 24% to $3,452 for the first three months of 2017, as compared to $2,794 in the comparable period of prior year.
Net sales for our crop business were up less than 1%, while net sales for our non-crop products were up 11%. A more detailed discussion of general market conditions and sales performance by category of products appears below. Overall net income was up at $0.12 per share as compared to $0.10 per share this time last year.
When considering the balance sheet, net debt reduced by $10,958 to $29,993 in the three month ended March 31, 2017. This compares with $40,951 at December 31, 2016 and $65,763 at the same time last year. Inventory ended the quarter at $122,279, which is in line with our sales and inventory planning for the 2017. In comparison, inventory at this time last year was $144,415.
RESULTS OF OPERATIONS
Quarter Ended March 31:
| Net sales: | 2017 | 2016 | Change | % Change |
|---|---|---|---|---|
| Insecticides | $37,942 | $33,106 | $4,836 | 15% |
| Herbicides/soil fumigants/fungicides | 20,021 | 24,685 | (4,664) | -19% |
| Other, including plant growth regulators | 3,392 | 3,277 | 115 | 4% |
| Total crop | 61,355 | 61,068 | 287 | 0% |
| Non-crop | 9,318 | 8,406 | 912 | 11% |
| $70,673 | $69,474 | $1,199 | 2% | |
| Cost of sales: | ||||
| Insecticides | $23,545 | $22,199 | $1,346 | 6% |
| Herbicides/soil fumigants/fungicides | 10,324 | 13,861 | (3,537) | -26% |
| Other, including plant growth regulators | 1,850 | 1,330 | 520 | 39% |
| Total crop | 35,719 | 37,390 | (1,671) | -4% |
| Non-crop | 4,870 | 4,581 | 289 | 6% |
| $40,589 | $41,971 | $(1,382) | -3% | |
| Gross profit: | ||||
| Insecticides | $14,397 | $10,907 | $3,490 | 32% |
| Herbicides/soil fumigants/fungicides | 9,697 | 10,824 | (1,127) | -10% |
| Other, including plant growth regulators | 1,542 | 1,947 | (405) | -21% |
| Gross profit crop | 25,636 | 23,678 | 1,958 | 8% |
| Gross profit non-crop | 4,448 | 3,825 | 623 | 16% |
| $30,084 | $27,503 | $2,581 | 9% | |
| Gross margin crop | 42% | 39% | ||
| Gross margin non-crop | 48% | 46% | ||
| Total gross margin | 43% | 40% |
| Net sales: | 2017 | 2016 | Change | % Change |
|---|---|---|---|---|
| US | $52,244 | $49,855 | $2,389 | 5% |
| International | 18,429 | 19,619 | (1,190) | -6% |
| $70,673 | $69,474 | $1,199 | 2% |
Generally speaking, the improved quarterly sales performance was driven by three factors. First, our cotton products generated strong sales arising from increased cotton acres (which USDA estimates will be up about 21% in the 2017 growing season) and higher anticipated pest pressure. Second, we experienced increased sales in products used on peanuts (for which USDA forecasts a 9% increase in planted acres) sugar beets, sugar cane and fruits and vegetables. Third, our non-crop products, particularly commercial pest control products and our mosquito adulticide, recorded higher sales for the period. Partially offsetting these increases were lower sales of our corn herbicide into the Midwest market, slower sales of soil fumigants due to wet weather in the Western US, and a decline in international sales.
Across our crop business, net sales of our insecticides group were up approximately 15% to end at $37,942, as compared to $33,106 during the first quarter of 2016. Within this segment, net sales of our non-granular insecticides used in crop applications increased significantly, as compared to the same period of the prior year. Our cotton insecticide Bidrin® posted significantly increased sales due to an expected increase in 2017 cotton acres, as noted above, and an anticipated increase in foliar pest pressure, as compared to extremely low infestation levels of 2016. Further, net sales of our granular soil insecticides were up approximately 2%. This increase was due to the strong performance of our non-corn insecticides, including Mocap® and Nemacur®, which are used primarily outside the U.S. market, Thimet®, which is used primarily in peanuts and sugar cane and Counter®, which is largely used for nematode control in corn and sugar beets.
Within the group of herbicides/fungicides/fumigants used in crop applications, net sales for the first quarter of 2017 declined by approximately 19% to $20,021 from $24,685 in the comparable period of 2016. Net sales of our herbicide products declined 23%, due to reduced sales of our corn herbicide, Impact® in light of competitive market conditions and rain-delayed planting in the Midwest market. Further, sales of our Scepter® soybean product, sold in the U.S. market, and our products Hyvar® and Krovar®, which are sold primarily in international markets, were down. Offsetting these declines we saw sales of Dacthal® increase nearly 40% during the first quarter for use on a wide variety of high value vegetable crops. However, our soil fumigants business declined by approximately 11% from the prior year’s first quarter due to excessively wet weather in the Western and Southeast regions which inhibits or delays the application of these liquid products.
Within the group of other products (which includes plant growth regulators, molluscicides and tolling activity), net sales were up about 4%, as compared to the first quarter of 2016. Lower quarterly sales of our growth regulator product NAA were more than offset by increased sales of our Metaldehyde granules and SmartBlock potato sprout inhibitor. There was a small decline in toll manufacturing revenue during this year’s first quarter.
Our non-crop sales ended the first quarter of 2017 up 11% at $9,318, as compared to $8,406 for the same period of the prior year. Contributing factors were higher sales of our insecticide products for commercial pest control and a year-over-year increase in our aerial-applied mosquito adulticide Dibrom.. These positive factors offset lower quarterly sales of our pharmaceutical products.
Our international sales ended at $18,429, as compared to $19,619 for the first quarter of the prior year, driven by lighter sales of our Hyvar and Krovar herbicides, somewhat offset by the continuing strong performance of our mainstay Mocap and Nemacur insecticide brands.
Our cost of sales for the first quarter of 2017 ended at $40,589 or 57% of net sales. This compares to $41,971 or 60% of net sales in the same period of 2016. The decrease in cost of sales as a percentage of net sales in 2017 was primarily the result of three drivers: first, our purchasing team has achieved raw material price reductions of about 0.8% in the period; second, our manufacturing performance improved; and third, the Company made more sales with higher margins in 2017 primarily driven by strong market performance in some of our key markets.
Gross profit for the first quarter of 2017 improved by $2,581, or 9%, to end at $30,084, as compared to $27,503 for the first quarter of 2016. Gross margin percentage ended at 43% in the first quarter of 2017, as compared to 40% in the first quarter of the prior year. This strong performance was primarily driven by strong raw material purchasing, methodical inventory management and solid sales mix performance.
Operating expenses increased by $2,078 to $24,951 for the three months ended March 31, 2017, as compared to the same period in 2016. The differences in operating expenses by department are as follows:
| 2017 | 2016 | Change | % Change | |
|---|---|---|---|---|
| Selling | $6,706 | $6,241 | $465 | 7% |
| General and administrative | 7,704 | 7,328 | 376 | 5% |
| Research, product development and regulatory | 5,697 | 4,457 | 1,240 | 28% |
| Freight, delivery and warehousing | 4,844 | 4,847 | (3) | 0% |
| $24,951 | $22,873 | $2,078 | 9% |
- Selling expenses increased by $465 to end at $6,706 for the three months ended March 31, 2017, as compared to the same period of 2016. The main drivers were an increase in marketing activities and a loss on foreign currency transactions.
- General and administrative expenses increased by $376 to end at $7,704 for the three months ended March 31, 2017, as compared to the same period of 2016. The main drivers were increased long-term incentive compensation costs and legal costs.
- Research, product development costs and regulatory expenses increased by $1,240 to end at $5,697 for the three months ended March 31, 2017, as compared to the same period of 2016. The main drivers were increased product defense costs and increased business development cost including our new SIMPAS system.
- Freight, delivery and warehousing costs for the three months ended March 31, 2017 were $4,844 or 6.9% of sales as compared to $4,847 or 7.0% of sales for the same period in 2016. This improvement was primarily driven by reduced inventory levels driving lower warehouse costs and the mix of sales, including lower sales of our high volume bulk fumigant products, in comparison to the same period of the prior year.
Interest costs net of capitalized interest, were $298 in the first three months of 2017, as compared to $541 in the same period of 2016. Interest costs are summarized in the following table:
Average Indebtedness and Interest expense
| Q1 2017 Average Debt | Interest Expense | Interest Rate | Q1 2016 Average Debt | Interest Expense | Interest Rate | |
|---|---|---|---|---|---|---|
| Revolving line of credit (average) | $44,217 | $258 | 2.3% | $76,227 | $482 | 2.5% |
| Notes payable | — | — | — | 44 | — | — |
| Amortization of deferred loan fees | — | 62 | — | — | 63 | — |
| Amortization of other deferred liabilities | — | 9 | — | — | 10 | — |
| Other interest expense | — | 7 | — | — | — | — |
| Subtotal | $44,217 | $336 | 3.0% | $76,271 | $555 | 2.9% |
| Capitalized interest | — | (38) | — | — | (14) | — |
| Total | $44,217 | $298 | 2.7% | $76,271 | $541 | 2.8% |
The Company’s average overall debt for the three months ended March 31, 2017 was $44,217, as compared to $76,271 for the three months ended March 31, 2016. During the quarter, we continued to focus on managing our working capital and controlling our usage of revolving debt. As can be seen from the table above, our effective bank interest rate on our revolving line of credit was 2.3% for the three months ended March 31, 2017, as compared to 2.5% in 2016.
Income tax expense increased by $320 to end at an expense of $1,380 for the three months ended March 31, 2017, as compared to $1,060 for the comparable period in 2016. The effective tax rate for the quarter was 28.5%, as compared to 25.9% in the same period of the prior year. The change in effective tax rate is primarily driven by improved year on year financial performance in jurisdictions with higher tax rates. Furthermore, the effective tax rate for all interim periods is based on the projected income for the full year and is subject to ongoing review and adjustment by management.
During the three months ended March 31, 2017 we recognized a loss of $42 on our investment in TyraTech. This compared to a loss of $82 recognized in the comparable period of 2016. This reflected the latest information regarding the forecast for their financial performance for 2016.
Non-controlling interest amounted to a gain of $39 in the three months ended March 31, 2017, as compared to a loss of $153 in the same period of the prior year. Non-controlling interest represents the share of net income or loss that is attributable to the minority stockholder of our majority owned subsidiary, Envance.
Our overall net income for the first three months of 2017 was $3,452 or 0.12 per basic and diluted share, as compared to $2,794 or $0.10 per basic and diluted share in the same quarter of 2016.
LIQUIDITY AND CAPITAL RESOURCES
The Company generated $17,170 of cash from operating activities in the first three months of 2017, as compared to $9,590 in the same period of the prior year. This arose from the following: first, net income of $3,413, as compared to $2,947; second, non-cash depreciation, amortization of intangibles and other long term assets and discounted future liabilities generated $5,368, as compared to $5,416 in the prior year; third, stock based compensation of $1,080 as compared to $421 in the same quarter of 2016; and fourth, other non-cash adjustments including loss from equity method investment provided net cash inflow of $9,911, as compared to $8,866 in the same period of 2016.
As of March 31, 2017, our working capital reduced to $126,023, as compared to $130,001 at December 31, 2016. This change was mainly driven by reductions in accounts receivable which was caused by two factors: first, customer decisions regarding the take up or otherwise of market driven early payment incentives; and second, the specific mix of sales, customers and terms agreed upon for sales in the prior three to six months. This time last year our working capital amounted to $154,629.
During the three months ended March 31, 2017, net sales ended up 2% at $70,673, as compared to the same period of 2016. At March 31, 2017 accounts receivable decreased by 13%, as compared to the balance as of March 31, 2016. During the first quarter of 2017 the level of accounts receivable decreased by $11,422, as compared to December 31, 2016. This change is driven by customer decisions related to timing of early pay and by the mix of sales of products, customers and regions in the three to six months prior to March 31, 2017.
Our deferred revenues decreased by $394 as some customers utilized their advance payments for purchases made during the quarter ended March 31, 2017. In the same period of the prior year deferred revenues decreased by $1,848.
Inventories ended at $122,279, which was an increase of $1,366 in comparison to December 31, 2016. This increase was somewhat lower than we reported for the same period of the prior year. It is normal at this point in the agricultural season to see our inventories increase as we work to supply grower demand in a timely manner. This year we continued to hold back inventory build to focus on managing our working capital levels. Furthermore, in the first three months of 2017, we purchased less inventory than in the comparable period of the prior year. It should be noted that the Company purchases and holds raw material, intermediate or finished goods inventory from time to time based on a single annual purchase from a single source or supplier, potentially resulting in peaks in the carrying value of the inventory. In comparison, inventories at March 31, 2016 were $22,136 higher at $144,415. As of March 31, 2017, we believe our inventories are valued at the lower of cost or market.
The Company accrues programs in line with the growing season upon which specific products are targeted. Typically crop products have a growing season that ends on September 30th each year. During the three months ended March 31, 2017, the Company made accruals in the amount of $13,543. Programs are primarily paid out to customers either in the final quarter of the fiscal year or the first quarter of the next fiscal year. During the first three months of 2017, the Company made payments in the amount of $6,931. Payments are not generally significant in the second and third quarters of each fiscal year. During the three months ended March 31, 2016, the Company accrued $13,369 and made payments in the amount of $5,738.
Timing of payments made on prepaid expenses and other assets caused an increase of $1,126, which is normal at this time in the year and compares to $1,036, this time last year. In 2017, our accounts payables went down by $3,025 as compared to an increase of $13,031 in the same period of 2016. This year, we held down manufacturing and purchased less inventory than we had during the comparable period of the prior year.
The Company utilized $3,380 for investing activities during the three months ended March 31, 2017, as compared to $3,998 during the same period of 2016. The Company made investments in capital expenditures in the current year, primarily focused on expanding plant capabilities. Furthermore, the Company made a small product line acquisition in the first quarter of 2017. During the same period of the prior year the Company made an investment in a Belgian company that develops biological plant protection products that can be used for the control of pests and disease of agricultural crops and a small level of spending on the manufacturing plant.
Financing activities utilized $10,986 principally by paying down on the line of credit during the three months ended March 31, 2017, as compared to $3,253 for the same purpose this time last year. This included a net repayment of $11,000 against our senior credit facility, as compared to $2,600 for the same period last year. Further, the Company received $53 upon vesting of shares and exercise of stock options and received $250 from the sale of common stock under its Employee Stock Purchase Plan, as compared to $315 for the same period of last year.
The Company has a revolving line of credit that is shown as long-term debt in the condensed consolidated balance sheets at March 31, 2017 and December 31, 2016. The Company has no short-term debt at March 31, 2017 and December 31, 2016. These are summarized in the following table:
| Long-term indebtedness ($000's) | March 31, 2017 | December 31, 2016 |
|---|---|---|
| Revolving line of credit | $30,400 | $41,400 |
| Deferred loan fees | (407) | (449) |
| Total indebtedness | $29,993 | $40,951 |
The Company has three key covenants to its senior, secured credit facility with its banking syndicate. The covenants are as follows: (1) the Company must maintain its borrowings below a certain consolidated funded debt ratio (taking into account the Company’s twelve month trailing EBITDA), (2) the Company has a limitation on its annual spending on the acquisition of fixed asset capital additions, and (3) the Company must maintain a certain consolidated fixed charge coverage ratio. As of March 31, 2017 the Company met all covenants in that credit facility.
At March 31, 2017, based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to $119,994 under the credit facility agreement. This compares to an available borrowing capacity of $65,373 as of March 31, 2016. This improvement in available borrowing capacity arises from improved financial performance (as measured by EBITDA) for the trailing twelve month period and the reduction in borrowings achieved since the end of the first quarter of 2016.
We believe that anticipated cash flow from operations, existing cash balances and available borrowings under our senior credit facility will be sufficient to provide us with liquidity necessary to fund our working capital and cash requirements for the next twelve months.
RECENTLY ISSUED ACCOUNTING GUIDANCE
In November 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-18, Statement of Cash Flows (Topic 230). The new standard requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new standard is effective for fiscal years beginning after December 15, 2017. Based on the composition of the Company’s cash and cash equivalent, adoption of the new standard is not expected to have a material impact on our consolidated cash flows statements. We expect to adopt the standard for the financial year beginning January 1, 2018.
In October 2016 FASB issued ASU 2016-16, Income Taxes (Topic 740). Current US GAAP prohibits the recognition of current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to an outside party. Under the new standard, an entity is to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The new standard does not include new disclosure requirements; however, existing disclosure requirements might be applicable when accounting for the current and deferred income taxes for an intra-entity transfer of an asset other than inventory. The new standard is effective for annual periods beginning after December 15, 2017, including interim reporting periods within those annual periods. The Company has considered its activities with regard to such intra-entity transfers, does not expect the adoption of ASU 2016-16 to have a material impact on our consolidated financial statements and will adopt the standard for the financial year beginning January 1, 2018.
In August 2016, FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230). The new standard addresses eight specific classification issues within the current practice regarding the manner in which certain cash receipts and cash payments are presented. The new standard is effective for fiscal years beginning after December 15, 2017, with early adoption permitted. The Company has reviewed the eight specific issues addressed and does not believe that the adoption of ASU 2016-15 will have a material impact on its statement of cash flows. Further, the Company is currently considering the possible option for early adoption. At the latest the Company will adopt the revised standard for the financial year beginning January 1, 2018.
In February 2016, FASB issued ASU 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the consolidated financial statements, with certain practical expedients available. We will evaluate our operating lease arrangements to determine the impact of this amendment on the consolidated financial statements. The evaluation will include an extensive review of our leases, which are primarily related to our manufacturing sites, regional sales offices, lease vehicles, and office equipment. The ultimate impact will depend on the Company’s lease portfolio at the time the new standard is adopted. The Company expects to adopt ASU 2016-02 for the financial year beginning on January 1, 2019.
In May 2014, FASB issued ASU 2014-09, Revenue from Contracts with Customers. ASU 2014-09 outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. In March 2016, FASB issued an amendment to the standard, ASU 2016-08, to clarify the implementation guidance on principal versus agent considerations. Under the amendment, an entity is required to determine whether the nature of its promise is to provide the specified good or service itself (that is, the entity is a principal) or to arrange for that good or service to be provided by the other party (that is, the entity is an agent). In April 2016, FASB issued another amendment to the standard, ASU 2016-10, to clarify identifying performance obligations and the licensing implementation guidance, which retaining the related principles for those areas. The standard and the amendments are effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). This standard also requires enhanced disclosures regarding the nature, amount, timing, and uncertainty of revenue and cash flows. The adoption methods available ASU 2014-09 are being evaluated by the Company, and at this point, the adoption is not expected to have significant impact on the Company’s consolidated financial statements. The Company expects to adopt the new revenue recognition standard for the financial year beginning January 1, 2018.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
The Company continually re-assesses the critical accounting policies used in preparing its financial statements. In the Company’s Form 10-K filed with the SEC for the year ended December 31, 2016, the Company provided a comprehensive statement of critical accounting policies. These policies have been reviewed in detail as part of the preparation work for this Form 10-Q. After our review of these matters, we have determined that, during the subject reporting period, there has been no material change to the critical accounting policies that are listed in the Company’s Form 10-K for the year ended December 31, 2016.
Market risk
As filed, 1,252 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Company is exposed to market risk related to changes in interest rates, primarily from its borrowing activities. The Company’s indebtedness to its primary lender is evidenced by a line of credit with a variable rate of interest, which fluctuates with changes in the lender’s reference rate. For more information, please refer to the applicable disclosures in the Company’s Form 10-K filed with the SEC for the year ended December 31, 2016.
The Company conducts business in various foreign currencies, primarily in Europe, Mexico, Central and South America. Therefore changes in the value of the currencies of such countries or regions affect the Company’s financial position and cash flows when translated into U.S. Dollars. The Company has mitigated and will continue to mitigate a portion of its currency exchange exposure through natural hedges based on the operation of decentralized foreign operating companies in which the majority of all costs are local-currency based. Furthermore, the Company has established a procedure for covering forward exchange rates on specific purchase orders when appropriate. A 10% change in the value of all foreign currencies would have an immaterial effect on the Company’s financial position and cash flows.
Controls and procedures
As filed, 1,057 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
As of March 31, 2017, the Company has a comprehensive set of disclosure controls and procedures designed to ensure that all information required to be disclosed in our filings under the Securities Exchange Act (1934) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. As of March 31, 2017, the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer has concluded, based on their evaluation, that the Company’s disclosure controls and procedures are effective to provide reasonable assurance of the achievement of the objectives described above.
There were no changes in the Company’s internal controls over financial reporting that occurred during the most recent quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.
PART II. OTHER INFORMATION
The Company was not required to report any matters or changes for any items of Part II except as disclosed below.
Risk factors
As filed, 406 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Company continually re-assesses the business risks, and as part of that process detailed a range of risk factors in the disclosures in American Vanguard’s Report on Form 10-K for the fiscal year ended December 31, 2016, filed on March 7, 2017. In preparing this document, we have reviewed all the risk factors included in that document and find that there are no material changes to those risk factors.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 3 months2017-01-01 to 2017-03-31 | $40.6m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2017-01-01 to 2017-03-31 | $30.1m | us-gaap:GrossProfit |
| Operating income | 3 months2017-01-01 to 2017-03-31 | $5.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2017-01-01 to 2017-03-31 | $298.0k | us-gaap:InterestExpense |
| Income tax | 3 months2017-01-01 to 2017-03-31 | $1.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-01-01 to 2017-03-31 | $3.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-01-01 to 2017-03-31 | $0.12 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2017-01-01 to 2017-03-31 | $0.12 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2017-01-01 to 2017-03-31 | 29,654,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2017-01-01 to 2017-03-31 | $17.2m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Dividends paid | 3 months2017-01-01 to 2017-03-31 | $289.0k | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2017-03-31 | $10.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-03-31 | $221.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-03-31 | $422.6m | us-gaap:Assets |
| Current liabilities | At period end2017-03-31 | $95.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-03-31 | $135.1m | us-gaap:Liabilities |
| Long-term debt | At period end2017-03-31 | $30.0m | us-gaap:LongTermDebtNoncurrent |
| Short-term borrowings | At period end2017-03-31 | $0 | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2017-03-31 | $287.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-17-008743. Last ingested by Listed: Nov 11, 2026, 00:16 ET. Listed shows no prices and gives no investment advice.